Integrative network analysis reveals time-dependent molecular events underlying left ventricular remodeling in post-myocardial infarction patients.
To elucidate the time-resolved molecular events underlying the LV remodeling (LVR) process, we developed a large-scale network model that integrates the 24 molecular variables (plasma proteins and non-coding RNAs) collected in the REVE-2 study at four time points (baseline, 1month, 3months and 1year) after MI. The REVE-2 network model was built by extending the set of REVE-2 variables with their mechanistic context based on known molecular interactions (1310 nodes and 8639 edges). Changes in the molecular variables between the group of patients with high LVR (>20%) and low LVR (<20%) were used to identify active network modules within the clusters associated with progression of LVR, enabling assessment of time-resolved molecular changes. Although the majority of molecular changes occur at the baseline, two network modules specifically show an increasing number of active molecules throughout the post-MI follow up: one involved in muscle filament sliding, containing the major troponin forms and tropomyosin proteins, and the other associated with extracellular matrix disassembly, including matrix metalloproteinases, tissue inhibitors of metalloproteinases and laminin proteins. For the first time, integrative network analysis of molecular variables collected in REVE-2 patients with known molecular interactions allows insight into time-dependent mechanisms associated with LVR following MI, linking specific processes with LV structure alteration. In addition, the REVE-2 network model provides a shortlist of prioritized putative novel biomarker candidates for detection of LVR after MI event associated with a high risk of heart failure and is a valuable resource for further hypothesis generation.
Inserm, U1167, Univ. Lille, Institut Pasteur de Lille, FHU-REMOD-VHF, F-59000, Lille, France. Electronic address: florence.pinet@pasteur-lille.fr.
Florence
F
Pinet
Inserm, U1167, Univ. Lille, Institut Pasteur de Lille, FHU-REMOD-VHF, F-59000, Lille, France.
Marie
M
Cuvelliez
EdgeLeap B.V., Utrecht, The Netherlands.
Thomas
T
Kelder
Univ. Lille, Inserm, U1167, CHRU Lille, Institut Pasteur de Lille, F-59000, Lille, France.
Philippe
P
Amouyel
EdgeLeap B.V., Utrecht, The Netherlands.
Marijana
M
Radonjic
Univ. Lille, Inserm, U1167, CHRU Lille, Institut Pasteur de Lille, F-59000, Lille, France.
Christophe
C
Bauters
D000328:Adult; D000368:Aged; D017364:Collagenases / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D061965:Matrix Metalloproteinase Inhibitors / Q000378:metabolism*; D008875:Middle Aged; D008955:Models, Cardiovascular; D009203:Myocardial Infarction / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D011446:Prospective Studies; D013997:Time Factors; D014336:Troponin / Q000378:metabolism*; D020257:Ventricular Remodeling
D061965:Matrix Metalloproteinase Inhibitors; D014336:Troponin; D017364:Collagenases
Left ventricule remodeling; biomarkers; echocardiography; system biology